| __timestamp | Blueprint Medicines Corporation | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 49315000 |
| Thursday, January 1, 2015 | 14456000 | 75043000 |
| Friday, January 1, 2016 | 19218000 | 83749000 |
| Sunday, January 1, 2017 | 27986000 | 122682000 |
| Monday, January 1, 2018 | 47928000 | 207761000 |
| Tuesday, January 1, 2019 | 96388000 | 284812000 |
| Wednesday, January 1, 2020 | 157743000 | 317875000 |
| Friday, January 1, 2021 | 195293000 | 282660000 |
| Saturday, January 1, 2022 | 237374000 | 451421000 |
| Sunday, January 1, 2023 | 295141000 | 481871000 |
| Monday, January 1, 2024 | 359272000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Sarepta Therapeutics, Inc. and Blueprint Medicines Corporation have shown distinct strategies in optimizing these costs. From 2014 to 2023, Sarepta's SG&A expenses surged by approximately 878%, peaking in 2023. In contrast, Blueprint Medicines saw a more modest increase of around 3,640% over the same period, indicating a more aggressive expansion strategy.
Sarepta's expenses consistently outpaced Blueprint's, with 2023 figures showing Sarepta's costs were about 63% higher. This trend suggests Sarepta's focus on scaling operations, while Blueprint's gradual increase reflects a more controlled growth approach. Understanding these dynamics offers valuable insights into how biotech companies balance growth with cost management, a critical factor for investors and industry analysts alike.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Who Optimizes SG&A Costs Better? Zoetis Inc. or Sarepta Therapeutics, Inc.
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Insmed Incorporated vs Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. vs Walgreens Boots Alliance, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc. or MorphoSys AG: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Sarepta Therapeutics, Inc. or Evotec SE
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Celldex Therapeutics, Inc.